文献速递眼底病与葡萄膜炎神经眼科

甲氨蝶呤与传统改善病情抗风湿药治疗非前节型结节病相关葡萄膜炎的比较

Methotrexate versus conventional disease-modifying antirheumatic drugs in the treatment of non-anterior sarcoidosis-associated uveitis.
PubMed 文献 · Br J Ophthalmol · 2024-12-17

这项回顾性研究纳入58例非前节型结节病相关葡萄膜炎患者,比较甲氨蝶呤(MTX)、霉酚酸酯(MMF)和硫唑嘌呤(AZA)的安全性与疗效。调整糖皮质激素剂量和血管炎存在后,MTX组治疗失败中位时间显著长于MMF和AZA组,12个月复发风险较MMF降低一半以上,末次访视低视力比例显著更低。结论认为MTX似乎比AZA和MMF更有效,且安全性可接受。

要点

  • MTX组治疗失败中位时间34.5个月,显著长于MMF的8.4个月和AZA的16.8个月(p=0.020)。
  • MTX组12个月复发风险较MMF降低一半以上(p=0.046)。
  • 末次访视低视力比例MTX组4%、MMF组9%、AZA组57%(p=0.008)。

核心结论

  • 在非前节型结节病相关葡萄膜炎中,MTX似乎比AZA和MMF更有效,且安全性可接受。

研究设计与样本

  • 回顾性研究,纳入符合修订版国际眼部结节病工作组标准的非前节型结节病相关葡萄膜炎患者58例(MTX组33例、MMF组16例、AZA组9例)。
  • 共分析75线治疗(MTX组39线、MMF组24线、AZA组12线)。
  • 主要结局定义为至复发或发生导致停药的重度不良事件的中位时间。

主要发现

  • 调整糖皮质激素剂量和血管炎存在后,MTX组治疗失败中位时间34.5个月(IQR 11.8至未达到),MMF组8.4个月(3.1-22.9),AZA组16.8个月(8.0-90.1),p=0.020。
  • 12个月复发风险MTX组较MMF组降低一半以上(p=0.046)。
  • 末次访视低视力比例MTX组4%、MMF组9%、AZA组57%(p=0.008)。
  • 全部75线治疗中,MTX在3个月获得治疗反应方面优于MMF和AZA(OR 10.85;95%CI 1.13至104.6;p=0.039)。
  • 仅在MTX组观察到12个月时显著的糖皮质激素节省效应(p=0.035)。

临床怎么用

  • 原文结论认为MTX似乎比AZA和MMF更有效且安全性可接受,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To compare the safety and efficacy of methotrexate (MTX), mycophenolate mofetil (MMF) and azathioprine (AZA) in non-anterior sarcoidosis-associated uveitis. METHODS: Retrospective study including non-anterior sarcoidosis-associated uveitis according to the revised International Workshop on Ocular Sarcoidosis criteria. The primary outcome was defined as the median time to relapse or occurrence of serious adverse events leading to treatment discontinuation. RESULTS: 58 patients with non-anterior sarcoidosis-associated uveitis (MTX (n=33), MMF (n=16) and AZA (n=9)) were included. The time to treatment failure (ie, primary outcome) after adjustment for corticosteroids dose and the presence of vasculitis was significantly higher with MTX (median time of 34.5 months with MTX (IQR: 11.8 -not reached) vs 8.4 months (3.1-22.9) with MMF and 16.8 months (8.0-90.1) with AZA (p=0.020)). The risk of relapse at 12 months was more than twice lower in MTX as compared with MMF (p=0.046). Low visual acuity at the last visit was significantly lower with MTX (4% vs 9% in MMF vs 57% in AZA group (p=0.008)). Regarding all 75 lines of treatment (MTX (n=39), MMF (n=24) and AZA (n=12)), MTX was more effective than MMF and AZA to obtain treatment response at 3 months (OR 10.85; 95% CI 1.13 to 104.6; p=0.039). Significant corticosteroid-sparing effect at 12 months (p=0.035) was only observed under MTX. Serious adverse events were observed in 6/39 (15%), 5/24 (21%) and 2/12 (17%) with MTX, MMF and AZA, respectively. CONCLUSION: In non-anterior sarcoidosis-associated uveitis, MTX seems to be more efficient compared with AZA and MMF and with an acceptable safety profile.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Leclercq M, Sève P, Biard L, et al. Methotrexate versus conventional disease-modifying antirheumatic drugs in the treatment of non-anterior sarcoidosis-associated uveitis. Br J Ophthalmol. 2024. PMID: 39013629. doi:10.1136/bjo-2024-325163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。